Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03873740
Other study ID # EV71-SD-2018-01
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date November 6, 2018
Est. completion date January 23, 2019

Study information

Verified date March 2019
Source Sinovac Biotech Co., Ltd
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the immunogenicity and safety of sequential vaccination of two EV71 inactived vaccines in healthy infants aged 6-35 months.


Description:

This study is a opened,randomized and controlled phase Ⅳ clinical trial. The purpose of this study is to evaluate the immunogenicity and safety of sequential vaccination of two EV71 inactived vaccines in healthy infants aged 6-35 months. EV71 inactived vaccines(Vero cells)was manufactured by Sinovac Biotech Co., Ltd and EV71 inactived vaccines(Human diploid cells)was manufactured by Institute of Medical Biology Chinese Academy of Medical Sciences.300 infants aged between 6-35 months will be randomly assigned into experimental group in the ratio 1:1:1:1.The experimental group 1 received two doses EV71 inactived vaccines(Vero cells)on day 0 and 30. The experimental group 2 received two doses EV71 inactived vaccines (Human diploid cells)on day 0 and 30. The experimental group 3 received one dose EV71 inactived vaccines (Vero cells)on day 0 and one dose EV71 inactived vaccines (Human diploid cells)on day 30.The experimental group 4 received one dose EV71 inactived vaccines (Human diploid cells)on day 0 and one dose EV71 inactived vaccines (Vero cells)on day 30. To evaluate the immunogenicity of the vaccine, venous blood will be collected for the EV71 neutralizing antibody detection prior to vaccination and 30 days after the 2nd dose vaccination.


Recruitment information / eligibility

Status Completed
Enrollment 300
Est. completion date January 23, 2019
Est. primary completion date January 21, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 6 Months to 35 Months
Eligibility Inclusion Criteria: - Healthy volunteer aged 6-35 months; - Proven legal identity; - Guardians of the participants should be capable of understanding the written consent form, and such form should be signed before the infant being included into this study. Exclusion Criteria: - Prior vaccination with EV71 vaccine; - History of hand,foot and mouth disease; - Allergy to gentamicin; history of allergy to any vaccine or vaccine ingredient, or serious adverse reaction(s) to vaccination, such as urticaria,difficulty in breathing, angioneurotic edema, pain, etc; - Congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc; - Autoimmune diseases or immunodeficiency/immunosuppression; - Severe neurological disorders (epilepsy, convulsions or convulsions) or psychosis; - History of thyroidectomy, absence of spleen, functional absence of spleen, and any circumstances leading to absence of spleen or splenectomy; - Diagnosed coagulation function abnormal (e.g., coagulation factor deficiency, coagulation disorder, or platelet abnormalities) , or obvious bruising or coagulation disorders; - Any immunosuppressant, cytotoxic medicine, or inhaled corticosteroids (except corticosteroid spray for treatment of allergic rhinitis or corticosteroid treatment on surface for acute non-complicated dermatitis) in the past 6 months; - Receipt of any of the following products: 1. Blood product within 3 months prior to study entry; 2. Any live attenuated vaccine within 14 days prior to study entry; 3. Any subunit vaccine or inactivated vaccine within 7 days prior to study entry; 4. Any other study drugs within 30 days prior to study entry; - Acute disease or acute stage of chronic disease within 7 days prior to study entry; - Axillary temperature > 37.0?; - Any other factor that suggesting the volunteer is unsuitable for this study based on the opinions of investigators.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
EV71 inactived vaccine(Vero cells)
The EV71 inactived vaccine(Vero cells) was manufactured by Sinovac Biotech Co., Ltd.
EV71 inactived vaccine(Human diploid cells)
The EV71 inactived vaccine(Human diploid cells) was manufactured by Institute of Medical Biology Chinese Academy of Medical Sciences.

Locations

Country Name City State
China Rushan City Center for Disease Control and Prevention Rushan Shandong

Sponsors (2)

Lead Sponsor Collaborator
Sinovac Biotech Co., Ltd Shandong Province Centers for Disease Control and Prevention

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary The seroconversion rates (SCR) of the EV71 neutralizing antibody calculated based on the cutoff value of 1:8. Subjects whose pre-immune EV71 antibody level < 1:8 and post-immune antibody level = 1:8, or those whose pre-immune antibody level = 1:8 and the increase of post-immune EV71 antibody level = 4 folds are considered seroconverted 30 days after two doses
Secondary The incidences of adverse reactions after each does After each dose, a 30-minute safety observation will be conducted immediately. The body temperature, solicited local and general adverse events (AE) on day 0-7 were reported. Unsolicited adverse events on day 0-30 were also reported. Each AE case will be reviewed by the investigator to determine whether or not it was an adverse reaction (The vaccination-related AE). 0-30 days after each dose
Secondary The incidence of solicited local and general adverse events after each does After each dose, a 30-minute safety observation will be conducted immediately. The body temperature, solicited local and general adverse events (AE) on day 0-7 were reported. Each AE case will be reviewed by the investigator to determine whether or not it was an adverse reaction (The vaccination-related AE). 0-7 days after each dose
Secondary Incidence of serious adverse events (SAEs) during the period of safety monitoring Serious adverse events (SAEs) will be collected during the period of safety monitoring after each dose. 0-30 days after each dose
Secondary EV71 neutralizing antibody positive rate of each group after two doses. Subjects whose post-immune antibody level = 1:8 are considered antibody positive. 30 days after two doses
Secondary The Geometric mean titer (GMT) of the EV71 neutralizing antibody The GMT 30 days of each group after two doses. 30 days after two doses
Secondary The geometric mean fold increase (GMI) of the EV71 neutralizing antibody The GMI 30 days of each group after two doses. 30 days after two doses
See also
  Status Clinical Trial Phase
Recruiting NCT06063057 - Inactivated Bivalent Enterovirus Vaccine (Vero Cell) Phase I/II Clinical Trial Phase 1/Phase 2
Completed NCT04133584 - The Immunogenicity and Safety of the Vaccination of Inactivated Enterovirus 71 Vaccine and Seasonal Influenza Vaccine Phase 4
Completed NCT03241030 - Sucralfate to Improve Oral Intake in Children With Infectious Oral Ulcers: a Randomized, Double-blind, Placebo-Controlled Trial Phase 2
Completed NCT01255124 - Study on Dynamic Changes of the Maternal Anti-EV71 and Anti-CVA16 Antibody Levels in Infants and Young Children N/A
Completed NCT05637229 - A Serosurvey Study of Hand, Foot, and Mouth Disease in Indonesia
Recruiting NCT06146088 - Lot-to-lot Consistency Study of Three Commercial Batches of Enterovirus 71 Vaccine Phase 4
Active, not recruiting NCT06209398 - Immunogenicity of the Inactivated EV71 Vaccine Combined With Hepatitis B and Group A Meningococcal Vaccine Phase 4
Recruiting NCT01145664 - A Multi-Center Clinical Trial To Evaluate Chinese Herbal Medicines in the Treatment of Severe Hand-foot-mouth Disease N/A
Recruiting NCT01175915 - A Clinical Trial To Evaluate Reduning Injection in the Treatment of Mild Type of Hand, Foot, and Mouth Disease N/A
Completed NCT01182532 - A Clinical Trial to Evaluate the Effectiveness and Safety of Chinese Medicine in the Treatment of Mild Type of Hand, Foot, and Mouth Disease N/A
Completed NCT03281174 - Five-year Immune Persistence Study of Inactivated Enterovirus Type 71 (EV71) Vaccine N/A
Completed NCT03582761 - Efficacy Evaluation for Inactivated Vaccine (Vero Cell) Against EV71 Phase 4
Completed NCT03903926 - Efficacy Trial of a Commercial EV71 Vaccine Phase 4
Completed NCT02001233 - A Follow-up Study for a Phase III, Efficacy Trial in Inactivated Enterovirus Type 71 (EV71) Vaccine
Completed NCT03909074 - Clinical Trial of Enterovirus 71(EV71) Inactivated Vaccine in Children Aged 36-71 Months Phase 3
Completed NCT01769794 - Chinese Medicinal Treatment on Mild Hand, Foot, and Mouth Disease: Multicenter, Prospective, Randomized Double-blind, Placebo-controlled Study N/A
Recruiting NCT01182025 - A Clinical Trial to Evaluate the Effectiveness and Safety of Xiyanping Injection in the Treatment of Mild Type of Hand, Foot, and Mouth Disease N/A
Recruiting NCT06263439 - Surveillance of HFMD in Pediatric Outpatients
Not yet recruiting NCT05397587 - An Immunity Persistence Study of Enterovirus 71 Inactivated Vaccine (Vero Cell) Phase 4
Completed NCT04111432 - Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With Expanded Programme on Immunization Vaccines Phase 4